Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Tóm tắt
The CANAL Study (Concerted Action on Neutralizing Antibodies in severe hemophilia A) was designed to describe the relationship between treatment characteristics and inhibitor development in previously untreated patients with severe hemophilia A. This multicenter retrospective cohort study investigated 366 consecutive patients born between 1990 and 2000. The outcome was clinically relevant inhibitor development, defined as the occurrence of at least 2 positive inhibitor titers combined with a decreased recovery. Eighty-seven (24%) patients developed inhibitors (69 high titer [19%]). The incidence of inhibitors appeared to be associated with age at first treatment, decreasing from 41% for those treated within the first month of age to 18% in those treated after 18 months; after adjustment for treatment intensity, this association largely disappeared. Surgical procedures and peak treatment moments at start of treatment increased inhibitor risk (relative risk [RR], 3.7; 95% confidence interval [CI], 2.0-7.1; and RR, 3.3; CI, 2.1-5.3, respectively). Regular prophylaxis was associated with a 60% lower risk than on-demand treatment (RR, 0.4; CI, 0.2-0.8). Our findings suggest that the previously reported associated between an early age at first exposure and the risk of inhibitor development is largely explained by early, intensive treatment. The latter appears to be an independent risk factor for inhibitor development. In addition, early, regular prophylaxis may protect patients with hemophilia against the development of inhibitors.
Từ khóa
Tài liệu tham khảo
Gringeri, 2004, Health status and health-related quality of life of children with haemophilia from six West European countries., Haemophilia, 10, 26, 10.1111/j.1355-0691.2004.00876.x
Wight, 2003, The epidemiology of inhibitors in haemophilia A: a systematic review., Haemophilia, 9, 418, 10.1046/j.1365-2516.2003.00780.x
Goudemand, 1999, Hemophilia: treatment of patients with inhibitors: cost issues., Haemophilia, 5, 397, 10.1046/j.1365-2516.1999.00368.x
Aledort, 1998, Inhibitors occur more frequently in African-American and Latino haemophiliacs., Haemophilia, 4, 68, 10.1046/j.1365-2516.1998.0146c.x
Astermark, 2001, The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients., Haemophilia, 7, 267, 10.1046/j.1365-2516.2001.00510.x
Frommel, 1977, Genetic predisposition to develop factor VIII antibody in classic hemophilia., Clin Immunol Immunopathol, 8, 34, 10.1016/0090-1229(77)90089-7
Shapiro, 1984, Genetic predisposition to inhibitor formation., Prog Clin Biol Res, 150, 45
Schwaab, 1995, Haemophilia A: mutation type determines risk of inhibitor formation., Thromb Haemost, 74, 1402, 10.1055/s-0038-1649954
Frommel, 1981, HLA antigens and factor VIII antibody in classic hemophilia: European study group of factor VIII antibody., Thromb Haemost, 46, 687, 10.1055/s-0038-1653453
Hay, 1997, HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A: UKHCDO Inhibitor Working Party., Thromb Haemost, 77, 234, 10.1055/s-0038-1655944
Oldenburg, 1997, HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII., Thromb Haemost, 77, 238, 10.1055/s-0038-1655945
Astermark, 2006, Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A., Blood, 107, 3167, 10.1182/blood-2005-09-3918
Astermark, 2006, A bi-allelic polymorphism in the promoter region of the TNF-alfa gene influences the risk of inhibitor development in patients with hemophilia A [abstract]., Haemophilia, 12
1979, Development of factor VIII antibody in haemophilic monozygotic twins: European Study Group of Factor VIII Antibody., Scand J Haematol, 23, 64, 10.1111/j.1600-0609.1979.tb02856.x
Goudemand, 2006, Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A., Blood, 107, 46, 10.1182/blood-2005-04-1371
Lorenzo, 2001, Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age., Br J Haematol, 113, 600, 10.1046/j.1365-2141.2001.02828.x
van der Bom, 2003, Age at first treatment and immune tolerance to factor VIII in severe hemophilia., Thromb Haemost, 89, 475, 10.1055/s-0037-1613376
Santagostino, 2005, Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study., Br J Haematol, 130, 422, 10.1111/j.1365-2141.2005.05605.x
Chalmers, 2005, Early FVIII exposure and subsequent inhibitor development in children with severe haemophilia A [abstract]., J Thromb Haemost, 3
Fontes, 2004, Age at the beginning of factor VIII replacement is not a risk factor for inhibitor development in hemophilia A [abstract]., Haemophilia, 10, 14
Sharathkumar, 2003, Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A., J Thromb Haemost, 1, 1228, 10.1046/j.1538-7836.2003.00230.x
Morado, 2005, Prophylactic treatment effects on inhibitor risk: experience in one centre., Haemophilia, 11, 79, 10.1111/j.1365-2516.2005.00921.x
Calvez, 2006, Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required., Br J Haematol, 132, 798, 10.1111/j.1365-2141.2006.05989.x
Santagostino, 2006, Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required [letter]., Br J Haematol, 132, 800, 10.1111/j.1365-2141.2006.05990.x
Rosendaal, 1993, A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands: Dutch Hemophilia Study Group., Blood, 81, 2180, 10.1182/blood.V81.8.2180.2180
Lee, 1993, A note on the calculation of recovery for factor VIII infusions., Thromb Haemost, 69, 87, 10.1055/s-0038-1651555
Cox, 1972, Regression models and life tables., J Royal Stat Soc, B-34, 187
D'Agostino, 1990, Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study., Stat Med, 9, 1501, 10.1002/sim.4780091214
Kurtzke, 1989, On estimating survival; a tale of two censors., J Clin Epidemiol, 42, 169, 10.1016/0895-4356(89)90090-5
Harrell, Missing Data: With Applications to Linear Models, Logistic Regression, and Survival Analysis., 2001
Fredriks, 2000, Continuing positive secular growth change in The Netherlands 1955-1997., Pediatr Res, 47, 316, 10.1203/00006450-200003000-00006
Escuriola-Ettingshausen, 2004, The role of age at first exposure and therapy regimen on the development of neutralizing FVIII antibodies in hemophilia A [abstract]., Blood, 104
Kreuz, 2004, Inhibitor incidence in previously untreated patients (PUP) with hemophilia A and B - a 10-year follow up of the prospective multicenter study [abstract]., Blood, 104, 10.1182/blood.V104.11.3983.3983
Kreuz, 2005, Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation., Thromb Haemost, 93, 457, 10.1160/TH03-10-0643
Matzinger, 2002, The danger model: a renewed sense of self., Science, 296, 301, 10.1126/science.1071059
Goodeve, 2000, Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate): Recombinate PUP Study Group., Thromb Haemost, 83, 844, 10.1055/s-0037-1613931
Oldenburg, 2002, Inhibitor development in correlation to factor VIII genotypes., Haemophilia, 8, 23, 10.1046/j.1351-8216.2001.00134.x
Knobe, 2002, Breastfeeding does not influence the development of inhibitors in haemophilia., Haemophilia, 8, 657, 10.1046/j.1365-2516.2002.00655.x